QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gray, J. H. Articles by Giacomini, K. M. Search for Related Content PubMed PubMed Citation Articles by Gray, J. H. Articles by Giacomini, K. M.

Functional and Genetic Diversity in the Concentrative Nucleoside Transporter, CNT1, in Human Populations

Departments of Biopharmaceutical Sciences (J.H.G., L.M.M., R.P.O., T.J.U., K.M.G.) and Pharmaceutical Chemistry (C.C.H., M.K., S.J.J., D.S., T.E.F.), Genomics Core Facility, Program in Human Genetics (W.C., E.J.C.), University of California, San Francisco, San Francisco, California

The concentrative nucleoside transporter, CNT1 (SLC28A1), mediates the cellular uptake of naturally occurring pyrimidine nucleosides and many structurally diverse anticancer and antiviral nucleoside analogs. As a first step toward understanding whether genetic variation in CNT1 contributes to variation in the uptake and disposition of clinically used nucleoside analogs, we determined the haplotype structure and functionally analyzed all coding region variants of CNT1 identified in ethnically diverse populations (100 African Americans, 100 European Americans, 30 Asians, 10 Mexican Americans, and 7 Pacific Islanders) (Leabman et al., 2003). A total of 58 coding region haplotypes were identified using PHASE analysis, 44 of which contained at least one amino acid variant. More than half of the coding region haplotypes were population-specific. Using site-directed mutagenesis, 15 protein-altering CNT1 variants, including one amino acid insertion and one base pair (bp) deletion, were constructed and expressed in Xenopus laevis oocytes. All variant transporters took up [³H]thymidine with the exception of CNT1-Ser546Pro, a rare variant, and CNT1–1153del, a single bp deletion found at a frequency of 3% in the African American population. The bp deletion results in a frame-shift followed by a stop-codon. The anticancer nucleoside analog gemcitabine had a reduced affinity for CNT1-Val189Ile (a common CNT1 variant found at a frequency of 26%) compared with reference CNT1 (IC₅₀ = 13.8 ± 0.60 µM for CNT1-reference and 23.3 ± 1.5 µM for CNT1-Val189Ile, p < 0.05). These data suggest that common genetic variants of CNT1 may contribute to variation in systemic and intracellular levels of anti-cancer nucleoside analogs.

Address correspondence to: Dr. Kathleen M. Giacomini, Department of Biopharmaceutical Sciences, University of California-San Francisco, 513 Parnassus Ave., S-926, San Francisco, CA 94143-0446. E-mail: kmg{at}itsa.ucsf.edu

This article has been cited by other articles:

				K. Klein, G. A. Kullak-Ublick, M. Wagner, M. Trauner, and J. J. Eloranta Hepatocyte nuclear factor-4{alpha} and bile acids regulate human concentrative nucleoside transporter-1 gene expression Am J Physiol Gastrointest Liver Physiol, April 1, 2009; 296(4): G936 - G947. [Abstract] [Full Text] [PDF]

				S.-H. Tan, S.-C. Lee, B.-C. Goh, and J. Wong Pharmacogenetics in Breast Cancer Therapy Clin. Cancer Res., December 15, 2008; 14(24): 8027 - 8041. [Abstract] [Full Text] [PDF]

				I. Badagnani, R. A. Castro, T. R. Taylor, C. M. Brett, C. C. Huang, D. Stryke, M. Kawamoto, S. J. Johns, T. E. Ferrin, E. J. Carlson, et al. Interaction of Methotrexate with Organic-Anion Transporting Polypeptide 1A2 and Its Genetic Variants J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 521 - 529. [Abstract] [Full Text] [PDF]

				A. R. Erdman, L. M. Mangravite, T. J. Urban, L. L. Lagpacan, R. A. Castro, M. de la Cruz, W. Chan, C. C. Huang, S. J. Johns, M. Kawamoto, et al. The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics Am J Physiol Renal Physiol, April 1, 2006; 290(4): F905 - F912. [Abstract] [Full Text] [PDF]

				T. J. Urban, R. Sebro, E. H. Hurowitz, M. K. Leabman, I. Badagnani, L. L. Lagpacan, N. Risch, and K. M. Giacomini Functional genomics of membrane transporters in human populations Genome Res., February 1, 2006; 16(2): 223 - 230. [Abstract] [Full Text] [PDF]

				R. P. Owen, L. L. Lagpacan, T. R. Taylor, M. De La Cruz, C. C. Huang, M. Kawamoto, S. J. Johns, D. Stryke, T. E. Ferrin, and K. M. Giacomini FUNCTIONAL CHARACTERIZATION AND HAPLOTYPE ANALYSIS OF POLYMORPHISMS IN THE HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER, ENT2 Drug Metab. Dispos., January 1, 2006; 34(1): 12 - 15. [Abstract] [Full Text] [PDF]

				M. Muzi, D. A. Mankoff, J. R. Grierson, J. M. Wells, H. Vesselle, and K. A. Krohn Kinetic Modeling of 3'-Deoxy-3'-Fluorothymidine in Somatic Tumors: Mathematical Studies J. Nucl. Med., February 1, 2005; 46(2): 371 - 380. [Abstract] [Full Text] [PDF]

				Y. Lai, E.-W. Lee, C. C. Ton, S. Vijay, H. Zhang, and J. D. Unadkat Conserved residues F316 and G476 in the concentrative nucleoside transporter 1 (hCNT1) affect guanosine sensitivity and membrane expression, respectively Am J Physiol Cell Physiol, January 1, 2005; 288(1): C39 - C45. [Abstract] [Full Text] [PDF]